Medi caps Limited has notified BSE about the Securities and Exchange Board of India's circular dated January 30, 2026, which introduces a special window for transfer and dematerialisation of physical securities. The circular, bearing reference number HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026, aims to ease investment processes for shareholders holding physical securities.

Special Window Details

The SEBI circular establishes a dedicated facility for securities that were sold or purchased prior to April 1, 2019. This special window will remain operational for one year, commencing from February 5, 2026, and concluding on February 4, 2027.

Eligibility and Coverage

The facility extends beyond new applications to include previously submitted transfer requests that faced issues. Specifically, the window covers transfer requests that were:

• Earlier submitted but rejected
• Returned due to documentation deficiencies
• Remained unattended due to procedural requirement gaps

Transfer Conditions and Lock-in Period

Under the new facility, transferred securities will be subject to specific conditions. All securities processed through this window will be mandatorily credited to the transferee only in dematerialised mode. Additionally, these securities will be placed under a lock-in period of one year from the date of registration of transfer.

During the lock-in period, the securities cannot be:

• Transferred to another party
• Lien marked
• Pledged for any purpose

Shareholder Action Required

Medi-Caps Limited has advised shareholders to take advantage of this opportunity by submitting the required documents mentioned in the SEBI circular. All documentation should be furnished to the company's Registrar and Share Transfer Agents, Ankit Consultancy Private Limited, located at 60, Electronic Complex, Pardeshipura, Indore (M.P.) 452010.

Shareholders can access the complete SEBI circular through the official SEBI website for detailed information about documentation requirements and procedural guidelines. For any queries related to this facility, shareholders are encouraged to contact the RTA or the company directly through the provided email addresses.

Medi-Caps Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, presenting a mixed performance across its business segments. The Board of Directors approved these results in their meeting held on February 11, 2026, with the financial statements reviewed by statutory auditors Rawka & Associates.

Board Meeting and Regulatory Compliance

The company's Board of Directors convened on February 11, 2026, from 3:00 PM to 3:50 PM to consider and approve the unaudited standalone and consolidated financial results. The meeting was conducted under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with Managing Director Alok K Garg overseeing the proceedings.

Standalone Financial Performance

The company's standalone operations demonstrated a strong recovery in Q3FY26, reporting significant improvements across key financial metrics:

For the nine-month period ended December 31, 2025, standalone operations maintained profitability with a net profit of ₹17.42 lacs compared to a loss of ₹15.10 lacs in the corresponding period last year.

Consolidated Financial Results

The consolidated performance, which includes wholly-owned subsidiary Medgel Private Limited, showed continued challenges despite some improvement:

Segment-wise Performance Analysis

The company operates through two main business divisions with contrasting performance trajectories:

Real Estate Division:

• Generated revenue of ₹77.28 lacs in Q3FY26 from shop sales at Medi-caps Business Park
• Reported segment profit of ₹31.35 lacs compared to a loss of ₹26.47 lacs in Q3FY25
• Nine-month revenue reached ₹177.24 lacs with segment profit of ₹20.27 lacs

Pharma Division:

• Revenue of ₹352.66 lacs in Q3FY26 versus ₹376.26 lacs in Q3FY25
• Segment loss of ₹105.08 lacs in the current quarter
• Nine-month revenue declined to ₹722.67 lacs from ₹1698.78 lacs in the previous year

Subsidiary Performance

Medgel Private Limited, the company's wholly-owned subsidiary operating in the pharma segment, reported challenging financial metrics for the nine-month period:

Financial Position and Capital Structure

The company maintained a stable capital structure with paid-up equity share capital of ₹1247.00 lacs. Total comprehensive income for Q3FY26 on a consolidated basis was negative ₹16.44 lacs, showing improvement from the negative ₹257.11 lacs in Q3FY25.

Operational Highlights

Key operational developments during the quarter included:

• Revenue generation from real estate operations through shop sales at Medi-caps Business Park
• Continued focus on the pharma division despite operational challenges
• Maintenance of dual business model across real estate and pharmaceutical segments
• Compliance with Indian Accounting Standards and SEBI regulations
• Publication of results on company website and stock exchange platforms

The company's financial results reflect the ongoing transformation in its business mix, with real estate operations showing recovery while the pharma segment through its subsidiary continues to face operational headwinds. The results were prepared in accordance with Indian Accounting Standards and reviewed by the company's statutory auditors.